#USA #San Diego #Aethlon Medical #Hemopurifier #GNA Affinity Resin

Aethlon Medical Reports Promising Preclinical Data on Hemopurifier® for Long COVID Treatment

Aethlon Medical, Inc. has recently made headlines with its innovative research into the treatment of Long COVID, a condition that continues to plague millions following their COVID-19 infections. On November 20, 2025, the company published preclinical findings that reveal the potential of its Hemopurifier® device to effectively target harmful extracellular vesicles (EVs) in Long COVID patients, thereby significantly reducing associated inflammatory microRNAs.

Understanding Long COVID

Long COVID, characterized by prolonged symptoms after the initial COVID-19 infection, includes fatigue, cognitive impairments, and respiratory issues, affecting an estimated 44 to 48 million people in the United States. Despite significant investment in research, finding effective treatments has proven elusive, with a projected economic burden reaching $2 billion for affected individuals.

The Hemopurifier® is designed to eliminate harmful EVs, which are implicated in the pathophysiology of Long COVID. These vesicles can harbor microRNA and viral particles, contributing to inflammation and other complications. Aethlon Medical aims to alleviate these issues by utilizing the GNA affinity resin in the Hemopurifier®, targeting EVs through a combination of plasma separation and molecular binding.

The Research Breakthrough

In collaboration with the University of California, San Francisco, Aethlon Medical conducted a study analyzing plasma samples from Long COVID patients. The findings were striking: plasma from these patients exhibited heightened levels of both large and small EVs, particularly those marked by mannose, a sugar that the GNA resin targets for removal. Notably, when treated with the Hemopurifier®, there was a simultaneous reduction in the levels of inflammatory microRNAs associated with the JAK-STAT signaling pathway, suggesting not only a reduction in EVs but also a potential pathway for inflammation mitigation.

Dr. Steven P. LaRosa, Chief Medical Officer at Aethlon, expressed his excitement over these findings, indicating that this marked the first demonstration of GNA's efficacy in treating Long COVID. The implications of this are profound, aspiring to broaden the therapeutic applications of the Hemopurifier® beyond its primary focus on oncology.

Targeting Inflammation

The research hinted at the capability of the Hemopurifier® to downregulate inflammatory pathways while potentially activating tissue repair processes. Data indicated that the removal of specified microRNAs correlated with decreased inflammatory signaling, making it a hopeful candidate for future clinical trials aimed at Long COVID treatments.

James Frakes, Aethlon's CEO, emphasized the device's versatility in addressing multiple conditions, describing it as 'a pipeline within a single device.' The ongoing endeavors to further understand the Hemopurifier®’s impact on viral remnants also reflect the company's commitment to exploring every avenue in combating Long COVID and other related conditions.

Aethlon's Broader Vision

The Hemopurifier®, designated as a Breakthrough Device by the FDA, has shown success in various clinical applications, including cancer treatment and the elimination of life-threatening viral infections. Aethlon is hopeful that the Hemopurifier® can expand its indications to include Long COVID treatment, potentially ushering in a new era of therapeutic options for those suffering from this debilitating condition.

As the research progresses, Aethlon Medical remains at the forefront of developing transformative healthcare solutions, promising hope and relief for individuals grappling with the lingering effects of COVID-19. This preclinical data not only signifies a breakthrough for the company but also for the millions impacted by Long COVID, offering a glimmer of hope for effective treatment options in the future.

For more information about Aethlon Medical and their innovative products, visit Aethlon Medical's website.